5-氟-2-(甲硫基)苯甲醛 | 160503-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氟-2-(甲硫基)苯甲醛
• 英文名称: 5-fluoro-2-(methylsulfanyl)benzaldehyde
• 英文别名: 5-Fluoro-2-(methylthio)benzaldehyde；5-fluoro-2-methylsulfanylbenzaldehyde
• CAS: 160503-79-7
• 化学式: C₈H₇FOS
• 分子量: 170.207
• InChiKey: XOVNDEPQWXDIPA-UHFFFAOYSA-N

物化性质

• 沸点：
  246.2±30.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氟-2-(甲硫基)苯甲醛 在 potassium permanganate 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 54.0h， 生成 5-(5-Fluoro-2-methylsulfonylphenyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors

  摘要：

  Sorbinil (1), a spirocyclic hydantoin, is a potent inhibitor of the enzyme aldose reductase. Simulation of the rigid spirocyclic ring orientation found in sorbinil was achieved with nonspirocyclic 5-[5'-chloro-2'-(alkylsulfonyl)-phenyl]hydantoins and 5-[5'-chloro-2'-[(N-alkylamino)sulfonyl]phenyl]hydantoins. The 2'-substituent (SO2R) was sufficiently large to hinder rotation of the hydantoin ring, forcing an orientation similar to that of a spirocyclic hydantoin. Calculated conformational preference, X-ray data, and inhibitory IC50 values for these nonspirocyclic 2'-substituted (SO2R) phenylhydantoins are in accord with what is expected for spirocyclic hydantoins and comparable to those of sorbinil.

  DOI：

  10.1021/jm00126a011
• 作为产物：
  描述：

  (5-Fluoro-2-methylsulfanylphenyl)methanol 在 manganese(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 5-氟-2-(甲硫基)苯甲醛
  参考文献：
  名称：

  Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors

  摘要：

  Sorbinil (1), a spirocyclic hydantoin, is a potent inhibitor of the enzyme aldose reductase. Simulation of the rigid spirocyclic ring orientation found in sorbinil was achieved with nonspirocyclic 5-[5'-chloro-2'-(alkylsulfonyl)-phenyl]hydantoins and 5-[5'-chloro-2'-[(N-alkylamino)sulfonyl]phenyl]hydantoins. The 2'-substituent (SO2R) was sufficiently large to hinder rotation of the hydantoin ring, forcing an orientation similar to that of a spirocyclic hydantoin. Calculated conformational preference, X-ray data, and inhibitory IC50 values for these nonspirocyclic 2'-substituted (SO2R) phenylhydantoins are in accord with what is expected for spirocyclic hydantoins and comparable to those of sorbinil.

  DOI：

  10.1021/jm00126a011

文献信息

• [EN] IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS TRK INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-B]PYRIDAZINE UTILISÉS EN TANT QU'INHIBITEURS DE TRK
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2020016594A1

  公开（公告）日：2020-01-23

  The present invention relates to certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts of such compounds. The invention also relates to the processes for the preparation of the compounds, compositions containing the compounds, and the uses of such compounds and salts in treating diseases or conditions associated with tropomyosin-related kinase (Trk), activity. More specifically the invention relates to the compounds and their salts useful as inhibitors of Trk. (I) wherein R1, R2, R3, R4 and R5 are as defined herein.

  本发明涉及某些咪唑并[1,2-b]吡啶嗪化合物及该类化合物的药用盐。该发明还涉及制备这些化合物的方法、含有这些化合物的组合物，以及这些化合物和盐在治疗与肌球蛋白相关激酶（Trk）活性相关的疾病或症状中的用途。更具体地，本发明涉及作为Trk抑制剂有用的化合物及其盐。（I）其中R1、R2、R3、R4和R5如本文所定义。
• [EN] PHARMACEUTICAL COMPOSITIONS AND THEIR USES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2021148807A1

  公开（公告）日：2021-07-29

  The present invention relates to pharmaceutical compositions, such as topical compositions, comprising certain imidazo [1,2-b] pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising compounds of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.

  本发明涉及药物组合物，如局部组合物，包括某些咪唑并[1,2-b]吡啶嗪化合物以及这些化合物的药学上可接受的盐和/或溶剂。该发明还涉及制备药物组合物的过程，以及利用这些组合物治疗与肌球蛋白相关激酶（Trk）活性相关的疾病或症状。更具体地，本发明涉及包含式（I）化合物或其药学上可接受的盐和/或溶剂的局部药物组合物，这些化合物在抑制Trk方面是有用的。
• [EN] IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS<br/>[FR] IMIDAZO[1,2-B]PYRIDAZINES UTILISÉES EN TANT QU'INHIBITEURS DE TRK
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2020039209A1

  公开（公告）日：2020-02-27

  The present invention relates to certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts of such compounds. The invention also relates to the processes for the preparation of the compounds, compositions containing the compounds, and the uses of such compounds and salts in treating diseases or conditions associated with tropomyosin-related kinase (Trk), activity. More specifically the invention relates to the compounds and their salts useful as inhibitors of Trk. Formula (I) wherein R1, R2, R3, R4 and R5, L and Z are as defined herein.

  本发明涉及某些咪唑并[1,2-b]吡啶嗪化合物以及这些化合物的药用盐。本发明还涉及制备这些化合物的过程、含有这些化合物的组合物、以及这些化合物和盐在治疗与肌浆蛋白相关激酶（Trk）活性相关的疾病或症状中的用途。更具体地，本发明涉及作为Trk抑制剂有用的化合物及其盐。公式（I）中R1、R2、R3、R4和R5、L和Z的定义如本文所述。
• [EN] TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES TOPIQUES COMPRENANT DES COMPOSÉS IMIDAZO[1,2-B]PYRIDAZINE
  申请人：BENEVOLENTAI BIO LTD

  公开号：WO2021148805A1

  公开（公告）日：2021-07-29

  The present invention relates to pharmaceutical compositions, such as topical pharmaceutical compositions, comprising certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention also relates to the processes for the preparation of the pharmaceutical compositions, and the uses of such compositions in treating diseases or conditions associated with tropomyosin-related kinase (Trk) activity. More specifically the invention relates to topical pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salts and/or solvates thereof, which are useful in inhibiting Trk.

  本发明涉及药物组合物，例如局部药物组合物，包括某些咪唑[1,2-b]吡啶嗪化合物及该类化合物的药用可接受的盐和/或溶剂化合物。该发明还涉及制备药物组合物的方法，以及利用这些组合物治疗与肌浆蛋白相关激酶（Trk）活性相关的疾病或症状。更具体地，该发明涉及包含化合物（I）的局部药物组合物或其药用可接受的盐和/或溶剂化合物，这些组合物在抑制Trk方面是有用的。
• Chromium-catalyzed couplings of C(aryl)–SMe bonds for accessing arylated and alkylated benzaldehyde derivatives
  作者：Haohao Zeng、Shangru Yang、Chao Li、Fei Fan、Liang Ling、Meiming Luo、Xiaoming Zeng

  DOI：10.1039/d2cc01631a

  日期：——

  functionalized benzaldehydes under mild conditions. This reaction was promoted specifically by a low-cost and simple CrCl2 salt used as a precatalyst, enabling synchronous activations of ortho-C(aryl)–SMe and ortho′-C(aryl)–H bonds to achieve difunctionalization of benzaldimines. This work provided a strategy for accessing arylated, alkylated, and diarylated benzaldehyde derivatives as a result of

  这里描述的是铬催化的 C(芳基)-SMe 键断裂，导致在温和条件下与有机镁偶联得到官能化苯甲醛。该反应通过一种用作预催化剂的低成本且简单的 CrCl 2盐来特别促进，使邻-C(芳基)-SMe 和邻'-C(芳基)-H 键同步活化以实现苯扎亚胺的双官能化。由于 C(芳基)-SMe 和 C(芳基)-SMe/C(芳基)-H 键的偶联在具有成本效益的 Cr 催化作用下得到促进，这项工作提供了一种获取芳基化、烷基化和二芳基化苯甲醛衍生物的策略.